Polycystic ovary syndrome- Pipeline Insight, 2023

Polycystic ovary syndrome- Pipeline Insight, 2023

DelveInsight’s, “Polycystic ovary syndrome- Pipeline Insight, 2023” report provides comprehensive insights about 5+ companies and 5+pipeline drugs in Polycystic ovary syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Polycystic ovary syndrome: Understanding

Polycystic ovary syndrome: Overview

Polycystic ovarian syndrome (PCOS) is the most common hormonal disorder in females of reproductive age. It is characterized by two or more of the following: irregular menstrual periods, hyperandrogenism, and polycystic ovaries. Multiple morbidities are associated with PCOS, including infertility, metabolic syndrome, obesity, impaired glucose tolerance, type 2 diabetes mellitus (DM-2), cardiovascular risk, depression, obstructive sleep apnea (OSA), endometrial cancer, and nonalcoholic fatty liver disease/ nonalcoholic steatohepatitis (NAFLD/NASH).

Etiology

PCOS is a multifactorial disease. Several susceptible genes have been identified as contributors to the pathophysiology of the disease. These genes are involved in various levels of steroidogenesis and androgenic pathways. Twin studies have estimated about 70% heritability. Also, the environment is a fundamental component in the expression of these genes and the development and progression of the disease.

Two popular hypotheses postulate that individuals with a genetic predisposition exposed to certain environmental factors lead to the expression of PCOS features. The most common environmental factors include obesity and insulin resistance. Some hypotheses also include fetal androgen exposure.

Signs and Symptoms

Common signs of polycystic ovary syndrome (PCOS) include the following:

 Irregular menstrual periods—Menstrual disorders can include absent periods, periods that occur infrequently or too frequently, heavy periods, or unpredictable periods.

 Infertility—PCOS is one of the most common causes of female infertility.

 Obesity—As many as 4 in 5 women with PCOS are obese.

 Excess hair growth on the face, chest, abdomen, or upper thighs—This condition, called hirsutism, affects more than 7 in 10 women with PCOS.

 Severe acne or acne that occurs after adolescence and does not respond to usual treatments

 Oily skin

 Patches of thickened, velvety, darkened skin called acanthosis nigricans

 Multiple small fluid-filled sacs in the ovaries

Treatment

Lifestyle Modification

In overweight and obese PCOS women and adolescents, exercise and calorie-restrictive diets are the best first-line interventions for weight loss and IGT. Different studies have shown that hirsutism can improve as well as regulation of the menstrual cycle and ovulation. Low-carbohydrate diets have been used, hoping that these will have a better effect on hyperinsulinism, but studies have shown no difference in outcomes with low-carbohydrate diets.

Hormonal Contraceptive

First-line treatment for menstrual abnormalities, hirsutism, and acne is a hormonal contraceptive, either oral contraceptive, patch, or vaginal rings. The Endocrine Society does not favor any choice over another. The progestin component decreases LH levels, indirectly decreasing ovarian androgen production and increasing sex hormone-binding globulin.

""Polycystic ovary syndrome- Pipeline Insight, 2023"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycystic ovary syndrome pipeline landscape is provided which includes the disease overview and Polycystic ovary syndrome treatment guidelines. The assessment part of the report embraces, in depth Polycystic ovary syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polycystic ovary syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Polycystic ovary syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Polycystic ovary syndrome.

Polycystic ovary syndrome Emerging Drugs Chapters

This segment of the Polycystic ovary syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Polycystic ovary syndrome Emerging Drugs

Saroglitazar Magnesium: Zydus Cadila

LIPAGLYN (Saroglitazar) influences glucose metabolism as well as fat metabolism. It acts on certain receptors and helps in lowering high blood triglycerides as well as the glucose levels in the blood and improves insulin resistance. Lipaglyn (Saroglitazar) was launched in September 2013 in India, for treating Hypertriglyceridemia and Diabetic Dyslipidemia in Patients with Type 2 Diabetes not controlled by statins. Currently it is being investigated in Phase II trials for Polycystic Ovary Syndrome.

Further product details are provided in the report……..

Polycystic ovary syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Polycystic ovary syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Polycystic ovary syndrome

There are approx. 5+ key companies which are developing the therapies for Polycystic ovary syndrome. The companies which have their Polycystic ovary syndrome drug candidates in the most advanced stage, i.e. phase III.

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Polycystic ovary syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular

Intraocular

Intrathecal

Intravenous

Ophthalmic

Oral

Parenteral

Subcutaneous

Topical

Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

Oligonucleotide

Peptide

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polycystic ovary syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polycystic ovary syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycystic ovary syndrome drugs.

Polycystic ovary syndrome Report Insights

Polycystic ovary syndrome Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Polycystic ovary syndrome Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Polycystic ovary syndrome drugs?

How many Polycystic ovary syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycystic ovary syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polycystic ovary syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Polycystic ovary syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Spruce Biosciences

Zydus Therapeutics Inc.

AbbVie

YOUNGENE

Key Products

Tildacerfont

Saroglitazar Magnesium

Elagolix

YG1805